Mode
Text Size
Log in / Sign up
Early Phase 1 N=13 Randomized Triple-blind Treatment

Probiotics for Quality of Life in Autism Spectrum Disorders

Autism Spectrum Disorders · Anxiety

Enrolled (actual)
13
Serious AEs
0.0%
Results posted
Feb 2020
Primary outcome: Primary: Change in Gastrointestinal (GI) Module of the Pediatric Quality of Life Inventory (PedsQL) at From Baseline at Week 8 — 17.97; 7.98 Units on a scale

Study Design & Population

Study type
Interventional
Phase
Early Phase 1
Interventions
Maltose (placebo) (Drug); Visbiome Extra Strength (Drug)
Age
Pediatric · 3+ yrs
Sex
All
Sponsor
Ohio State University
Primary completion
Dec 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Gastrointestinal (GI) Module of the Pediatric Quality of Life Inventory (PedsQL) at From Baseline at Week 8
17.97; 7.98
SECONDARY
Change in Target Symptom Rating From Baseline at Week 8
-2.10; -0.60
SECONDARY
Change in Parent Anxiety Checklist--ASD From Baseline at Week 8
-6.20; -4.10
SECONDARY
Change in The Aberrant Behavior Checklist (ABC) From Baseline at Week 8
-1.80; -3.50; -2.60; -2.50; -1.20; -1.80
SECONDARY
Change in Social Responsiveness Scale (SRS) From Baseline at Week 8
-4.70; -1.70
SECONDARY
Children's Sleep Habits Questionnaire (CSHQ) at Week 8
42.80; 43.44
SECONDARY
Change in The Parenting Stress Index Short Form (PSI)
-9.60; -1.70

Summary

A randomized pilot trial of a probiotic for quality of life in autism spectrum disorder (ASD), targeting gastrointestinal (GI) symptoms.

Eligibility Criteria

Inclusion Criteria

  • have DSM-5 ASD on clinical evaluation by a doctoral-level diagnostician, confirmed by Autism Diagnostic Interview-Revised or Autism Diagnostic Observation Schedule;
  • be between 3 and 12 years old;
  • have >2 mo. abdominal pain, constipation, diarrhea, and/or vomiting, with an item-mean score >2 on at least one scale of the GI module of the PedsQL scale;
  • have clinical anxiety symptoms with an item mean of >1.0 (0-3 scale) on the new Autism Anxiety Scale.

Participants will be recruited from minority, poor, inner city, or rural populations.

Exclusion Criteria

  • Antibiotics in 2 months prior to enrolling;
  • Prior bowel surgery;
  • Chronic serious medical condition (e.g., diabetes);
  • Weight or height < 3rd %ile for age;
  • Chronic anti-inflammatory use within 2 months prior to enrolling;
  • History of inflammatory bowel disease, Celiac disease, or eosinophilic disorders (e.g., eosinophilic esophagitis);
  • Already taking probiotics within the previous 6 months.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02903030). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search